Release of proposals for utilization of medical data for the democratization and sophistication of healthcare | News Releases | Deloitte Tohmatsu Group | Deloitte

April 5, 2023

Deloitte Tohmatsu Group’s Deloitte Tohmatsu Consulting LLC (headquartered in Chiyoda-ku, Tokyo), Takeda Pharmaceutical Company Limited (headquartered in Chuo-ku, Tokyo), Integrity Healthcare Co., Ltd. (headquartered in Chuo-ku, Tokyo), Japan Eye Co., Ltd. BMW Corporation (headquartered in Chuo-ku, Tokyo) and all seven other volunteers today announced the “Democratization and Sophistication of Healthcare,” which summarizes the future vision, challenges, and countermeasures for medical data utilization. Proposals for utilization of medical data for

With the advent of the era of 100-year lifespans, it is essential to utilize digital technology and data in order to live out those 100 years in a healthy and meaningful way, both physically and mentally. However, in Japan, the utilization of “medical data” has not progressed as much as the progress of digital technology.

Pharmaceutical companies, platform operators, digital/technology companies, and consulting firms have held discussions based on their respective perspectives and experiences, and have compiled countermeasures that transcend the boundaries of industries and organizations rather than individual players. .

First of all, this proposal describes the “ideal future image” of the utilization of medical data that Japan should be heading toward. Appropriate utilization of medical data will revolutionize the healthcare experience in our lives, and its benefits are not limited to general consumers and patients, but also to healthcare professionals, pharmaceutical companies, medical device companies, and insurance companies. It benefits a wide range of stakeholders, including corporations, digital/technology companies, and governments.

On the other hand, regarding issues that hinder the formation of a data-circulating ecosystem, such as the delay in medical DX, the proliferation of medical data standards and lack of compatibility, and the shortage of data scientists, we will focus on objective facts and refer to cases in other countries. mention while On top of that, as countermeasures, 1) building an integrated/open platform, 2) forming a data circulation type ecosystem and pursuing sustainability, and 3) market transformation through rule-making, will be presented, and will lead to action from the private sector’s point of view. We assume that

In the future, based on this proposal, we will implement actions starting from private companies and promote the utilization of medical data by making the value of data utilization more concrete. In addition, we will contribute to the acceleration of the utilization of medical data by collaborating across industries and organizations and leading a major movement across the country.